Effectiveness of montelukast in overweight and obese atopic asthmatics

Among the 2 obese-asthma phenotypes (early-onset/atopic and late-onset/nonatopic), patients have increased asthma severity,1 decreased asthma control,1,2 and decreased response to inhaled corticosteroids (ICSs),3–6 the first-line treatment for all patients with persistent asthma. In vitro studies of rat alveolar macrophages have found that leptin enhances cysteinyl leukotriene production.7 In obese patients with asthma, body mass index (BMI) correlated with leukotriene synthesis,8 suggesting that leptin perpetuates cysteinyl leukotriene–mediated inflammation in obese patients with asthma.

http://ift.tt/2toY36q